Unlike the US FDA, the CHMP doesn't recommend approval for pre-chemo prostate cancer.
ApexOnco Front Page
Recent articles
ERAS-0015 data look good, but the company is punished for a pneumonitis death.
Intismeran autogene’s Interpath-001 trial reads out this year.
Armed with $75m the company takes a risky asset into the clinic.
The biotech licenses a China-developed anti-B7-H3 ADC.
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
GEN1286 looks dead, though MCLA-129 continues for now.
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
